Clinical Trial Update: Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease [Phase 3]

View source ↗

Summary

Phase 3 safety and tolerability comparison of the aclidinium bromide/formoterol fumarate fixed-dose combination versus formoterol fumarate in patients with mode…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Aclidinium bromide/formoterol fumarate (Aclidinium bromide/formoterol fumarate)
• FORMOTEROL FUMARATE (Formoterol fumarate dihydrate)

Snippet

Sponsor: AstraZeneca | Conditions: Chronic Obstructive Pulmonary Disease | Phase 3 | Status: COMPLETED | Results posted: 2017-05-11